Estimating the economic consequences of substance use and substance use disorders.

Manthey, Jakob; Hassan, Syed Ahmed; Carr, Sinclair; Kilian, Carolin; Kuitunen-Paul, Sören; Rehm, Jürgen

Manthey, Jakob; Hassan, Syed Ahmed; Carr, Sinclair; Kilian, Carolin; Kuitunen-Paul, Sören; Rehm, Jürgen.

Afiliación

Manthey J; Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany.
Hassan SA; Center for Interdisciplinary Addiction Research (ZIS), Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Carr S; Department of Psychiatry, Medical Faculty, University of Leipzig, Leipzig, Germany.
Kilian C; Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
Kuitunen-Paul S; Institute of Health Policy, Management and Evaluation, Toronto, Ontario, Canada.
Rehm J; Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany.

Expert Rev Pharmacoecon Outcomes Res ; 21(5): 869-876, 2021 Oct.

Article en En | MEDLINE | ID: mdl-33899647

Asunto(s)

Costo de Enfermedad; Costos de la Atención en Salud; Trastornos Relacionados con Sustancias/economía; Política de Salud; Humanos

Palabras clave

Avoidable costs; cost of illness; direct costs; economic benefits; economic costs; indirect costs; intangible costs; substance use; substance use disorders; taxation

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Costos de la Atención en Salud / Costo de Enfermedad / Trastornos Relacionados con Sustancias Tipo de estudio: Health_economic_evaluation Idioma: En Revista: Expert Rev Pharmacoecon Outcomes Res Asunto de la revista: FARMACOLOGIA Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google